Evidence map›Paper›PMID 30202601›Full record

ArticleBJPsych open2018

Characteristics of patients expressing an interest in ketamine treatment: results of an online survey.

Jolien K E Veraart, Sanne Y Smith-Apeldoorn, Hayley Trueman, Marrit K de Boer, Robert A Schoevers, Rupert McShane

Open access · goldAbstract read
In one paragraph

Article in BJPsych open, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Jolien K E VeraartDepartment of Psychiatry, University Medical Center Groningen and Research School Behavioral and Cognitive Neurosciences, University of Groningen, the Netherlands.
Sanne Y Smith-ApeldoornDepartment of Psychiatry, University Medical Center Groningen and Research School Behavioral and Cognitive Neurosciences, University of Groningen, the Netherlands.
Hayley TruemanClinical Practitioner, Oxford Health NHS Foundation Trust and Department of Psychiatry, University of Oxford, UK.
Marrit K de BoerPsychiatrist, Department of Psychiatry, University Medical Center Groningen and Research School Behavioral and Cognitive Neurosciences, University of Groningen, the Netherlands.
Robert A SchoeversProfessor, Department of Psychiatry, University Medical Center Groningen and Research School Behavioral and Cognitive Neurosciences, University of Groningen, the Netherlands.
Rupert McShaneClinical Practitioner, Oxford Health NHS Foundation Trust and Associate Professor, Department of Psychiatry, University of Oxford, UK.
University Medical Center Groningen · NLOxford Health NHS Foundation Trust · GBUniversity of Groningen · NLUniversity of Oxford · GB

Funding

Department of Health PB-PG-0408-16030
6 · The paper itself

Abstract

backgroundOff-label ketamine treatment has shown acute antidepressant effects that offer hope for patients with therapy-resistant depression. However, its potential for integration into treatment algorithms is controversial, not least because the evidence base for maintenance treatment with repeated ketamine administration is currently weak. Ketamine is also a drug of misuse, which has raised concerns regarding the target population. Little is known about which patients would seek ketamine treatment if it were more widely available.

aimsTo explore some of the characteristics of the patients actively seeking ketamine treatment.

methodAn online survey containing questions about duration of current depressive episode, number of antidepressants used and other comments was completed by patients who were exploring the internet regarding the possibility of ketamine for depression.

resultsOf the 1088 people who registered their interest, 93.3% reported depression, 64.3% reported a chronic course of their symptoms and in the past 10 years, 86.3% had tried at least two antidepressants. Desperation was a common theme, but this appeared to be competently expressed. A small minority (<8%) reported experience of illegal ketamine use.

conclusionsIt cannot be ruled out that patients with different degrees of treatment resistance and comorbidities will seek treatment with ketamine. This stresses the urgency to perform larger randomised controlled trials as well as to systematically monitor outcomes and adverse effects of ketamine, that is currently prescribed off-label for patients in need. DECLARATION OF INTEREST: R.M. is consulting and is Principal Investigator for Janssen trials of esketamine and is consulting for Eleusis.

Indexed as

antidepressantdepressionKetamineoff labeltreatment resistant

Identifiers

PMID30202601
PMCPMC6127959
OpenAlexW2892231541

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.